Life sciences growth requires payment rates to return to internationally comparable levels
Existing and proposed medicine payment rates of a quarter to a third of UK pharmaceutical company revenue are incompatible with government ambitions to grow the sector.
Read the full articleYou might also wanna read
UK Life Sciences Must Move From Innovation Pilots to National Adoption
The UK is not short of innovation. The challenge is building the national systems, funding routes and procurement models needed to turn prom
UK life sciences sector secures £3 billion investment
The UK's life sciences sector has attracted more than £3 billion in new public and private investment over the past 12 months. The post UK l
Life sciences pulled in over £3bn since since sector plan launched
The UK life sciences sector has attracted more than £3bn in new public-private investment in the past 12 months, marking the first year of a
Wall Street Is Betting on Eli Lilly’s GLP-1 Portfolio — It’s Missing the $1 Trillion Opportunity
The pharmaceutical industry is entering a new era where biology and artificial intelligence are converging. Drug discovery, once a slow proc
NHS Fast-tracks Life-changing Medicines in Landmark UK-US Access Overhaul
A new series of NHS pilot schemes could give patients access to innovative medicines months earlier while supporting investment in the UK's
Drug pricing in Canada
Long-awaited reforms to drug price regulations are delayed again.
Comments
Sign in to join the conversation.
No comments yet. Be the first.